Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Basilea Pharmaceutica has presented data on its antifungal BAL8557 showing that the drug has a promising safety and drug-drug interaction profile. Additional data also confirms broad-spectrum antifungal activity of the compound.
Subscribe to our email newsletter
The studies, presented at the International Society for Human and Animal Mycology meeting in Paris, show that BAL8557 had no significant impact on the pharmacokinetics of ciclosporin and a relatively modest effect on tacrolimus. Ciclosporin and tacrolimus are frequently used and important immunosuppressant drugs in transplant medicine. In addition, BAL8557 did not affect the kinetics of warfarin, a widely used anticoagulant drug.
Drug-drug interaction and safety profile are important aspects of new antifungal therapies as hospitalized patients requiring systemic antifungal therapies, such as HIV/AIDS, cancer or transplant patients, often have comprimed immune systems and receive multi-drug medications.
“BAL8557 has the potential to be a leading antifungal drug for the treatment of severe invasive fungal infections with its intravenous and oral formulations, a broad-spectrum and a promising drug-drug interaction profile,” said Dr Rienk Pypstra, chief development officer at Basilea.
BAL8557 was recently granted fast track designation by the FDA.